Evidence map›Paper›PMID 31916049›Full record

ArticleJournal of computer-aided molecular design2020

Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4.

Bo Wang, Ho-Leung Ng

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. RORγ Structural Plasticity and Druggability.International journal of molecular sciences · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bo WangBiochemistry & Molecular Biophysics, Kansas State University, 141 Chalmers Hall, 1711 Claflin Rd., Manhattan, KS, 66506, USA.
Ho-Leung NgBiochemistry & Molecular Biophysics, Kansas State University, 141 Chalmers Hall, 1711 Claflin Rd., Manhattan, KS, 66506, USA. hng@ksu.edu.ORCID 0000-0002-6415-1938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug Design Data Resource (D3R) Grand Challenge 4 (GC4) offered a unique opportunity for designing and testing novel methodology for accurate docking and affinity prediction of ligands in an open and blinded manner. We participated in the beta-secretase 1 (BACE) Subchallenge which is comprised of cross-docking and redocking of 20 macrocyclic ligands to BACE and predicting binding affinity for 154 macrocyclic ligands. For this challenge, we developed machine learning models trained specifically on BACE. We developed a deep neural network (DNN) model that used a combination of both structure and ligand-based features that outperformed simpler machine learning models. According to the results released by D3R, we achieved a Spearman's rank correlation coefficient of 0.43(7) for predicting the affinity of 154 ligands. We describe the formulation of our machine learning strategy in detail. We compared the performance of DNN with linear regression, random forest, and support vector machines using ligand-based, structure-based, and combining both ligand and structure-based features. We compared different structures for our DNN and found that performance was highly dependent on fine optimization of the L2 regularization hyperparameter, alpha. We also developed a novel metric of ligand three-dimensional similarity inspired by crystallographic difference density maps to match ligands without crystal structures to similar ligands with known crystal structures. This report demonstrates that detailed parameterization, careful data training and implementation, and extensive feature analysis are necessary to obtain strong performance with more complex machine learning methods. Post hoc analysis shows that scoring functions based only on ligand features are competitive with those also using structural features. Our DNN approach tied for fifth in predicting BACE-ligand binding affinities.

Indexed as

Drug DesignMolecular Docking SimulationNeural Networks, ComputerAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBinding SitesEnzyme InhibitorsHumansLigandsMacrocyclic CompoundsProtein BindingAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanEnzyme InhibitorsLigandsMacrocyclic CompoundsBACEBeta-secretase 1Binding affinityD3RDeep neural networkDockingMachine learningStructure-based drug design

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.